[Pefloxacin in the treatment of patients with mucoviscidosis].
It was shown that microbial flora isolated from the bronchial secretion of 39 patients with mucoviscidosis in 1999-2001 consisted in one third (32.8%) of S. aureus strains. Evaluation of pefloxacin efficacy in the case of monoinfection and pathogens association revealed potent antistaphylococcal effect of the drug. Positive result was demonstrated in 82.3% cases by the 7th day. Among the side effects dominated arthropathy which disappeared at the period from 3 days to 3 months after drug administration was stopped.
D000293:Adolescent; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001980:Bronchi / Q000378:metabolism / Q000382:microbiology; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D006801:Humans; D015366:Pefloxacin / Q000009:adverse effects / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D015366:Pefloxacin
Mesto pefloksatsina v lechenii bol'nykh mukovistsidozom.